PAI-1 genetic polymorphisms influence septic patients' outcomes by regulating neutrophil activity.
Journal
Chinese medical journal
ISSN: 2542-5641
Titre abrégé: Chin Med J (Engl)
Pays: China
ID NLM: 7513795
Informations de publication
Date de publication:
20 Aug 2023
20 Aug 2023
Historique:
received:
13
10
2022
medline:
22
8
2023
pubmed:
13
7
2023
entrez:
13
7
2023
Statut:
ppublish
Résumé
Plasminogen activator inhibitor-1 (PAI-1) plays an important role in the pathophysiology of sepsis, but the exact mechanism remains debatable. In this study, we investigated the associations among the serum levels of PAI-1, the incidence of 4G/5G promoter PAI-1 gene polymorphisms, immunological indicators, and clinical outcomes in septic patients. A total of 181 patients aged 18-80 years with sepsis between November 2016 and August 2018 in the intensive care unit in the Xinhua Hospital were recruited in this retrospective study, with 28-day mortality as the primary outcome. The initial serum level of PAI-1 and the presence of rs1799768 single nucleotide polymorphisms (SNPs) were examined. Univariate logistic regression and multivariate analyses were performed to determine the factors associated with different genotypes of PAI-1, serum level of PAI-1, and 28-day mortality. The logistic analysis suggested that a high serum level of PAI-1 was associated with the rs1799768 SNP of PAI-1 (4G/4G and 4G/5G) (Odds ratio [OR]: 2.49; 95% confidence interval [CI]: 1.09, 5.68). Furthermore, a high serum level of PAI-1 strongly influenced 28-day mortality (OR 3.36; 95% CI 1.51, 7.49). The expression and activation of neutrophils (OR 0.96; 95% CI 0.93, 0.99), as well as the changes in the expression patterns of cytokines and chemokine-associated neutrophils (OR: 1.00; 95% CI: 1.00, 1.00), were both regulated by the genotype of PAI-1. Genetic polymorphisms of PAI-1 can influence the serum levels of PAI-1, which might contribute to mortality by affecting neutrophil activity. Thus, patients with severe sepsis might clinically benefit from enhanced neutrophil clearance and the resolution of inflammation via the regulation of PAI-1 expression and activity.
Sections du résumé
BACKGROUND
BACKGROUND
Plasminogen activator inhibitor-1 (PAI-1) plays an important role in the pathophysiology of sepsis, but the exact mechanism remains debatable. In this study, we investigated the associations among the serum levels of PAI-1, the incidence of 4G/5G promoter PAI-1 gene polymorphisms, immunological indicators, and clinical outcomes in septic patients.
METHODS
METHODS
A total of 181 patients aged 18-80 years with sepsis between November 2016 and August 2018 in the intensive care unit in the Xinhua Hospital were recruited in this retrospective study, with 28-day mortality as the primary outcome. The initial serum level of PAI-1 and the presence of rs1799768 single nucleotide polymorphisms (SNPs) were examined. Univariate logistic regression and multivariate analyses were performed to determine the factors associated with different genotypes of PAI-1, serum level of PAI-1, and 28-day mortality.
RESULTS
RESULTS
The logistic analysis suggested that a high serum level of PAI-1 was associated with the rs1799768 SNP of PAI-1 (4G/4G and 4G/5G) (Odds ratio [OR]: 2.49; 95% confidence interval [CI]: 1.09, 5.68). Furthermore, a high serum level of PAI-1 strongly influenced 28-day mortality (OR 3.36; 95% CI 1.51, 7.49). The expression and activation of neutrophils (OR 0.96; 95% CI 0.93, 0.99), as well as the changes in the expression patterns of cytokines and chemokine-associated neutrophils (OR: 1.00; 95% CI: 1.00, 1.00), were both regulated by the genotype of PAI-1.
CONCLUSIONS
CONCLUSIONS
Genetic polymorphisms of PAI-1 can influence the serum levels of PAI-1, which might contribute to mortality by affecting neutrophil activity. Thus, patients with severe sepsis might clinically benefit from enhanced neutrophil clearance and the resolution of inflammation via the regulation of PAI-1 expression and activity.
Identifiants
pubmed: 37439338
doi: 10.1097/CM9.0000000000002316
pii: 00029330-990000000-00698
pmc: PMC10431590
doi:
Substances chimiques
Plasminogen Activator Inhibitor 1
0
SERPINE1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1959-1966Informations de copyright
Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.
Références
Huang M, Cai S, Su J. The pathogenesis of sepsis and potential therapeutic targets. Int J Mol Sci 2019;20: 5376. doi: 10.3390/ijms20215376.
doi: 10.3390/ijms20215376
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016;315: 801–810. doi: 10.1001/jama.2016.0287.
doi: 10.1001/jama.2016.0287
Sherwani S, Khan MWA. Cytokine response in SARS-CoV-2 infection in the elderly. J Inflamm Res 2020;13: 737–747. doi: 10.2147/jir.s276091.
doi: 10.2147/jir.s276091
Jin C, Chen J, Gu J, Zhang W. Gut-lymph-lung pathway mediates sepsis-induced acute lung injury. Chin Med J 2020;133: 2212–2218. doi: 10.1097/cm9.0000000000000928.
doi: 10.1097/cm9.0000000000000928
Huang W, Liu DW, Wang GJ, Zhang HM, Zhou GS, Liu JJ, et al. Serum microtubule-associated protein light chain 3 type II levels correlate with aggravation and multi-organ dysfunction in septic patients. Chin Med J 2021;134: 1732–1734. doi: 10.1097/cm9.0000000000001640.
doi: 10.1097/cm9.0000000000001640
Wang L, Ma XD, He HW, Su LX, Guo YH, Shan GL, et al. Analysis of factors influencing 3-and 6-h compliance with the surviving sepsis campaign guidelines based on medical-quality intensive care unit data from China. Chin Med J 2021;134: 1747–1749. doi: 10.1097/cm9.0000000000001362.
doi: 10.1097/cm9.0000000000001362
Claushuis TA, van Vught LA, Scicluna BP, Wiewel MA, Klein Klouwenberg PM, Hoogendijk AJ, et al. Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients. Blood 2016;127: 3062–3072. doi: 10.1182/blood-2015-11-680744.
doi: 10.1182/blood-2015-11-680744
Pudjiadi AH, Adhyanisitha K, Pusponegoro HD, Suyoko DEM, Satari HI, Kaswandani N. The association between plasminogen activator inhibitor type-1 and clinical outcome in paediatric sepsis. Blood Coagul Fibrinolysis 2020;31: 377–381. doi: 10.1097/MBC.0000000000000931.
doi: 10.1097/MBC.0000000000000931
Hoshino K, Kitamura T, Nakamura Y, Irie Y, Matsumoto N, Kawano Y, et al. Usefulness of plasminogen activator inhibitor-1 as a predictive marker of mortality in sepsis. J Intensive Care 2017;5: 42. doi: 10.1186/s40560-017-0238-8.
doi: 10.1186/s40560-017-0238-8
Koyama K, Madoiwa S, Nunomiya S, Koinuma T, Wada M, Sakata A, et al. Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: A prospective observational study. Crit Care 2014;18: R13. doi: 10.1186/cc13190.
doi: 10.1186/cc13190
Gupta KK, Xu Z, Castellino FJ, Ploplis VA. Plasminogen activator inhibitor-1 stimulates macrophage activation through toll-like receptor-4. Biochem Biophys Res Commun 2016;477: 503–508. doi: 10.1016/j.bbrc.2016.06.065.
doi: 10.1016/j.bbrc.2016.06.065
Praetner M, Zuchtriegel G, Holzer M, Uhl B, Schaubächer J, Mittmann L, et al. Plasminogen activator inhibitor-1 promotes neutrophil infiltration and tissue injury on ischemia-reperfusion. Arterioscler Thromb Vasc Biol 2018;38: 829–842. doi: 10.1161/ATVBAHA.117.309760.
doi: 10.1161/ATVBAHA.117.309760
Kwak SH, Wang XQ, He Q, Fang WF, Mitra S, Bdeir K, et al. Plasminogen activator inhibitor-1 potentiates LPS-induced neutrophil activation through a JNK-mediated pathway. Thromb Haemost 2006;95: 829–835. doi: 10.1160/TH05-12-0782.
doi: 10.1160/TH05-12-0782
Renckens R, Roelofs JJTH, Bonta PI, Florquin S, de Vries CJM, Levi M, et al. Plasminogen activator inhibitor type 1 is protective during severe gram-negative pneumonia. Blood 2007;09: 59–1601. doi: 10.1182/blood-2006-05-025197.
doi: 10.1182/blood-2006-05-025197
Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia – a review. Crit Care Med 2006;34: 871–877. doi: 10.1097/01.CCM.0000201882.23917.B8.
doi: 10.1097/01.CCM.0000201882.23917.B8
Zheng YX, Zhang ZH, Huang YB, Wang JP, Sang L, Xu YH, et al. Identification of differentially expressed genes and signaling pathways in neutrophils during sepsis-induced immunosuppression via bioinformatics analysis. Chin Med J 2022;135: 2131–2133. doi: 10.1097/cm9.0000000000001878.
doi: 10.1097/cm9.0000000000001878
Lu X, Xue L, Sun W, Ye J, Zhu Z, Mei H. Identification of key pathogenic genes of sepsis based on the Gene Expression Omnibus database. Mol Med Rep 2018;17: 3042–3054. doi: 10.3892/mmr.2017.8258.
doi: 10.3892/mmr.2017.8258
Jarahzadeh MH, Jafari M, Seifi-Shalamzari N, Ferdosian F, Bahrami R, Raee-Ezzabadi A, et al. Association of PAI-1 4G/5G and ACE I/D polymorphisms with susceptibility to pediatric sepsis: Evidence from a meta-analysis. Fetal Pediatr Pathol 2022;41: 242–258. doi: 10.1080/15513815.2020.1775736.
doi: 10.1080/15513815.2020.1775736
Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: Comparing current criteria. Crit Care Med 2006;34: 625–631. doi: 10.1097/01.ccm.0000202209.42491.38.
doi: 10.1097/01.ccm.0000202209.42491.38
Taylor FB Jr., Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86: 1327–1330. doi: 10.1055/s-0037-1616068.
doi: 10.1055/s-0037-1616068
Richards G, Levy H, Laterre P, Feldman C, Woodward B, Bates BM, et al. CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS. J Intensive Care Med 2011;26: 34–40. doi: 10.1177/0885066610383949.
doi: 10.1177/0885066610383949
Ringelstein M, Jung A, Berger K, Stoll M, Madlener K, Klötzsch C, et al. Promotor polymorphisms of plasminogen activator inhibitor-1 and other thrombophilic genotypes in cerebral venous thrombosis: A case-control study in adults. J Neurol 2012;59: 2287–2292. doi: 10.1007/s00415-012-6477-7.
doi: 10.1007/s00415-012-6477-7
Eriksson P, Kallin B, van't Hooft FM, Båvenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995;92: 1851–1855. doi: 10.1073/pnas.92.6.1851.
doi: 10.1073/pnas.92.6.1851
Lorente L, Martín MM, Borreguero-León JM, Barrios Y, Solé-Violán J, Ferreres J, et al. The 4G/4G genotype of PAI-1 polymorphism is associated with higher plasma PAI-1 concentrations and mortality in patients with severe sepsis. PLoS One 2015;10: e0129565. doi: 10.1371/journal.pone.0129565.
doi: 10.1371/journal.pone.0129565
Shi Q, Mu X, Hong L, Zheng S. SERPINE1 rs1799768 polymorphism contributes to sepsis risk and mortality. J Renin Angiotensin Aldosterone Syst 2015;16: 1218–1224. doi: 10.1177/1470320315614714.
doi: 10.1177/1470320315614714
Li L, Nie W, Zhou H, Yuan W, Li W, Huang W. Association between plasminogen activator inhibitor-1 -675 4G/5G polymorphism and sepsis: A meta-analysis. PLoS One 2013;8: e54883. doi: 10.1371/journal.pone.0054883.
doi: 10.1371/journal.pone.0054883
Liu X, Shen Y, Wang H, Ge Q, Fei A, Pan S. Prognostic significance of neutrophil-to-lymphocyte ratio in patients with sepsis: A Prospective Observational Study. Mediators Inflamm 2016;2016: 8191254. doi: 10.1155/2016/8191254.
doi: 10.1155/2016/8191254
Costantini E, Carlin M, Porta M, Brizzi M. Type 2 diabetes mellitus and sepsis: State of the art, certainties and missing evidence. Acta Diabetol 2021;58: 1139–1151. doi: 10.1007/s00592-021-01728-4.
doi: 10.1007/s00592-021-01728-4
Levi M, van der Poll T. Coagulation and sepsis. Thromb Res 2017;149: 38–44. doi: 10.1016/j.thromres.2016.11.007.
doi: 10.1016/j.thromres.2016.11.007
McColl SR, St-Onge M, Dussault AA, Laflamme C, Bouchard L, Boulanger J, et al. Immunomodulatory impact of the A2A adenosine receptor on the profile of chemokines produced by neutrophils. FASEB J 2006;20: 187–189. doi: 10.1096/fj.05-4804fje.
doi: 10.1096/fj.05-4804fje